Trial · NCT02787057
Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
NCT02787057, Not applicable, Completed, Peking University First Hospital; results first posted 2020-03-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis. Trials, record NCT02787057. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02787057
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
- NCT number
- NCT02787057
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 80 participants, actual
- Lead sponsor
- Peking University First Hospital
- Conditions
- Peritoneal Dialysis Associated Peritonitis
- Interventions
- vancomycin, moxifloxacin, ceftazidime
- First posted
- 2016-06-01
- Last updated
- 2020-03-26
- Results first posted
- 2020-03-26
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Cure Rate | within 4 weeks of completion of therapy | complete cure was defined as complete resolution of peritonitis (normalization of body temperature, resolution of abdominal pain, clearing of dialysate, and PD effluent neutrophil count less than 100 cells/mL and proportion of polynuclear cell less than 50%) by using antibiotics alone without relapse within 4 weeks of completion of therapy |
| Secondary | Primary Response Rate | on day 10 by using antibiotics alone | Primary response was defined as resolution of peritonitis (normalization of body temperature, resolution of abdominal pain, clearing of dialysate, and PD effluent neutrophil count less than 100 cells/mL and proportion of polynuclear cell less than 50%) on day 10 by using antibiotics alone |
| Secondary | Primary Treatment Failure Rate | after 3 days of treatment by the assigned antibiotics | Primary treatment failure was defined as the presence of fever, abdominal pain, and turbid peritoneal dialysate, and if the total peritoneal WBC counts is \>50% of the pretreatment values after 3 days of treatment by the assigned antibiotics |
| Secondary | Secondary Treatment Failure Rate | after 6 to 8 days of treatment | Secondary treatment failure was defined as treatment failure despite adjustment of antibiotics or changing to second line antibiotics for 3 to 5 days in patients with primary treatment failure |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete Cure Rate | within 4 weeks of completion of therapy | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Primary Response Rate | on day 10 by using antibiotics alone | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Primary Treatment Failure Rate | after 3 days of treatment by the assigned antibiotics | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Secondary Treatment Failure Rate | after 6 to 8 days of treatment | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Cure Rate | Control Group | 32 | Participants | ||
| Complete Cure Rate | Study Group | 31 | Participants | ||
| Primary Response Rate | Control Group | 32 | Participants | ||
| Primary Response Rate | Study Group | 27 | Participants | ||
| Primary Treatment Failure Rate | Control Group | 8 | Participants | ||
| Primary Treatment Failure Rate | Study Group | 13 | Participants | ||
| Secondary Treatment Failure Rate | Control Group | 5 | Participants | ||
| Secondary Treatment Failure Rate | Study Group | 4 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Control Group | 40 | |
| Overall Study | STARTED | Study Group | 40 | |
| Overall Study | COMPLETED | Control Group | 40 | |
| Overall Study | COMPLETED | Study Group | 40 | |
| Overall Study | NOT COMPLETED | Control Group | 0 | |
| Overall Study | NOT COMPLETED | Study Group | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea | Gastrointestinal disorders | Control Group | 0 | 40 | 0 |
| other | nausea | Gastrointestinal disorders | Study Group | 1 | 40 | 1 |
| other | rash | Skin and subcutaneous tissue disorders | Control Group | 1 | 40 | 1 |
| other | rash | Skin and subcutaneous tissue disorders | Study Group | 0 | 40 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Control Group | ||
| Total, all-cause mortality | Study Group | ||
| Total, other adverse events | Control Group | 1 | 40 |
| Total, other adverse events | Study Group | 1 | 40 |
| Total, serious adverse events | Control Group | 0 | 40 |
| Total, serious adverse events | Study Group | 0 | 40 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Study Group vs Control Group: Complete Cure Rate | Trial comparisons |
| Study Group vs Control Group: Secondary Treatment Failure Rate | Trial comparisons |
| Study Group vs Control Group: Primary Response Rate | Trial comparisons |
| Study Group vs Control Group: Primary Treatment Failure Rate | Trial comparisons |
| Study Group vs Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02787057
GET https://conductscience.org/api/trials/v1/NCT02787057/registered